NCT01181310View on ClinicalTrials.gov

Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Dementia
Interventions
DRUG

A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine

Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.

DRUG

B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg

Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.

DRUG

C: MK-3134 25 mg + Scopolamine 0.5 mg

A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.

DRUG

D: Donepezil 10 mg + Scopolamine 0.5 mg

A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

DRUG

E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg

A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01181310 - Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED) | Biotech Hunter | Biotech Hunter